N. Desai
Molecular Biology · Journal of Clinical Oncology · 2002–2012
A researcher in the Science corpus: 6 papers; trusts 6 researchers and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 16 citations into it
- Biomaterials — 13 citations into it; #850 of 2,152 by trust here, #686 by citations
- Cancer Research — 8 citations into it
- Biomedical Engineering — 5 citations into it
- Materials Chemistry — 5 citations into it; #5,604 of 11,513 by trust here, #7,401 by citations
Whom N. Desai trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- M. Dobrovolskaia
- Rakesh K. Jain
- R. Duncan
- Theresa M. Allen
- K. Greish
- A. Nel
- Mark E. Davis
- S. McNeil
- Paolo Antonio Netti
- O. Farokhzad
Who trusts N. Desai overall
Papers from N. Desai's perspective
Ordered by how strongly the researchers N. Desai trusts endorse each paper. Same corpus, a different order for every researcher.
- Transport of molecules across tumor vasculature (Cancer Metastasis Review)
- Role of extracellular matrix assembly in interstitial transport in solid tumors. (Cancer Research)
- Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. (Journal of Controlled Release)
- Ligand-targeted therapeutics in anticancer therapy (Nature Reviews. Cancer)
- Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. (Journal of Controlled Release)
- Immunological properties of engineered nanomaterials (Nature Nanotechnology)
- New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer… (Journal of the National Cancer Institute)
- Long-circulating and target-specific nanoparticles: theory to practice. (Pharmacological Reviews)
- Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. (Proceedings of the National Academy of Sciences of the United States of America)
- Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. (Methods)
Their papers
- Challenges in Development of Nanoparticle-Based Therapeutics (2012) — 981 citations
- Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. (2006) — 1,109 citations
- Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. (2011) — 1,030 citations
- Protein nanoparticles as drug carriers in clinical medicine. (2008) — 736 citations
- Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. (2005) — 1,927 citations
- Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. (2002) — 649 citations